Real-world diagnostic landscape and incidence of pulmonary hypertension in adult congenital heart disease patients using administrative claims data in Japan

被引:0
作者
Ishizu, Tomoko [1 ]
Hayashi, Yasuhiro [2 ,3 ]
Tokushige, Natsuko [2 ]
Omura, Junichi [2 ]
机构
[1] Univ Tsukuba, Inst Med, Dept Cardiol, Tsukuba, Japan
[2] Janssen Pharmaceut KK, Med Affairs Div, Tokyo, Japan
[3] Janssen Pharmaceut KK, Med Affairs Div, 5-2,Nishi Kanda 3 Chome,Chiyoda Ku, Tokyo 1010065, Japan
关键词
Pulmonary hypertension; Eisenmenger's syndrome; adult congenital heart disease; diagnostic testing; real-world settings; NATRIURETIC PEPTIDE BNP; ARTERIAL-HYPERTENSION; TERMINAL PROBNP; POPULATION; FAILURE;
D O I
10.1080/03007995.2024.2323632
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although pulmonary hypertension (PH) and Eisenmenger's syndrome (ES) are common complications in adult congenital heart disease (ACHD), the frequency of diagnostic tests and the incidence of PH/ES in patients with ACHD in Japanese clinical practice are unclear. Therefore, we sought to clarify the frequency of diagnostic tests and incidence of PH/ES in patients with ACHD using the Medical Data Vision (MDV) database, the largest anonymized database of diagnosis procedure combination hospitals in Japan. Methods: We conducted a retrospective cohort study using the MDV database (April 2008 to December 2021) of patients with ACHD (International Classificaiton of Diseases, 10th revision codes: Q203-204, Q210-213, Q250) aged >= 15 years. The frequency of laboratory/clinical tests and the incidence of PH/ES were calculated. Subgroup analyses were performed for the periods 2008-2015 and 2016-2021. Results: Overall, 28219 ACHD patients were extracted from the MDV database (females 56.3%, males 43.7%; mean +/- standard deviation age 44.7 +/- 23.5 years). The mean +/- standard deviation follow-up period was 2.5 +/- 2.7 years. The frequencies of electrocardiography, ultrasonography, brain natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), right heart catheterization, and pulmonary function tests (DLCO) were 2149.8, 1054, 1233, 340, 40.0, and 6.0 per 1000 person-years, respectively. The incidence rate of PH/ES was 32.8 per 1000 person-years. The incidence rate of PH/ES increased from 24.6 to 46.7 per 1000 person-years from 2008-2015 to 2016-2021. Conclusion: We have clarified the frequency of diagnostic tests related to PH/ES and the incidence of PH/ES in patients with ACHD in clinical practice in Japan, including non-specialist institutions for PH. [GRAPHICS] .
引用
收藏
页码:555 / 565
页数:11
相关论文
共 35 条
  • [1] Anderson James J, 2022, JACC Asia, V2, P538, DOI 10.1016/j.jacasi.2022.04.008
  • [2] Eisenmenger syndrome: diagnosis, prognosis and clinical management
    Arvanitaki, Alexandra
    Giannakoulas, George
    Baumgartner, Helmut
    Lammers, Astrid Elisabeth
    [J]. HEART, 2020, 106 (21) : 1638 - 1645
  • [3] Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease
    Chiu, Shuenn-Nan
    Lu, Chun-Wei
    Lin, Ming-Tai
    Chen, Chun-An
    Wu, Mei-Hwan
    Wang, Jou-Kou
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (07):
  • [4] Left Ventricular Function in Patients with Pulmonary Arterial Hypertension: The Role of Two-Dimensional Speckle Tracking Strain
    Correa, Ricardo de Amorim
    de Oliveira, Fernanda Brito
    Barbosa, Marcia M.
    Barbosa, Jose Augusto A.
    Carvalho, Tais Soares
    Barreto, Michele Campos
    Campos, Frederico Thadeu A. F.
    Pereira Nunes, Maria Carmo
    [J]. ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2016, 33 (09): : 1326 - 1334
  • [5] Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study
    Emmons-Bell, Sophia
    Johnson, Catherine
    Boon-Dooley, Alexandra
    Corris, Paul A.
    Leary, Peter J.
    Rich, Stuart
    Yacoub, Magdi
    Roth, Gregory A.
    [J]. PULMONARY CIRCULATION, 2022, 12 (01)
  • [6] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
    Galie, Nazzareno
    Humbert, Marc
    Vachiery, Jean-Luc
    Gibbs, Simon
    Lang, Irene
    Torbicki, Adam
    Simonneau, Gerald
    Peacock, Andrew
    Noordegraaf, Anton Vonk
    Beghetti, Maurice
    Ghofrani, Ardeschir
    Gomez Sanchez, Miguel Angel
    Hansmann, Georg
    Klepetko, Walter
    Lancellotti, Patrizio
    Matucci, Marco
    McDonagh, Theresa
    Pierard, Luc A.
    Trindade, Pedro T.
    Zompatori, Maurizio
    Hoeper, Marius
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (01) : 67 - +
  • [7] Bosentan Improves Exercise Capacity in Adolescents and Adults After Fontan Operation The TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) Study
    Hebert, Anders
    Mikkelsen, Ulla R.
    Thilen, Ulf
    Idorn, Lars
    Jensen, Annette S.
    Nagy, Edit
    Hanseus, Katarina
    Sorensen, Keld E.
    Sondergaard, Lars
    [J]. CIRCULATION, 2014, 130 (23) : 2021 - 2030
  • [8] Humbert M, 2022, EUROPEAN HEART
  • [9] Validity of congenital malformation diagnoses in healthcare claims from a university hospital in Japan
    Ishikawa, Tomofumi
    Oyanagi, Gen
    Obara, Taku
    Noda, Aoi
    Morishita, Kei
    Takagi, Shuyu
    Inoue, Ryusuke
    Kawame, Hiroshi
    Mano, Nariyasu
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (07) : 975 - 978
  • [10] Joint Research Group Societies, 2018, GUIDELINES TREATMENT